title: [Pharmaconutrition with parenteral selenium in sepsis].
abstract: Critical illness is characterized by oxidative stress which leads to multiple organ failure, and sepsis-related organ dysfunction remains the most common cause of death in the intensive care unit. Over the last 2 decades, different antioxidant therapies have been developed to improve outcomes in septic patients. According to recent evidence, selenium therapy should be considered the cornerstone of the antioxidant strategies. Selenium given as selenious acid or sodium selenite should be considered as a drug or pharmaconutrient with prooxidant and cytotoxic effects when a loading dose in intravenous bolus form is administered, particularly in the early stage of severe sepsis/septic shock. To date, several phase ii trials have demonstrated that selenium therapy may be able to decrease mortality, improve organ dysfunction and reduce infections in critically ill septic patients. The effect of selenium therapy in sepsis syndrome must be confirmed by large, well designed phase iii clinical trials. The purpose of this review is to discuss current evidence on selenium pharmaconutrition in sepsis syndrome.
authors.affiliation: Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
authors.forename: P L
authors.initials: PL
authors.lastname: Langlois
authors.affiliation: Hospital Municipal de Cubatão, São Paulo, Brasil.
authors.forename: L F
authors.initials: LF
authors.lastname: de Oliveira Figliolino
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland, Auckland, Nueva Zelanda.
authors.forename: G
authors.initials: G
authors.lastname: Hardy
authors.affiliation: Cátedra de Medicina Intensiva, Centro de Tratamiento Intensivo, Hospital de Clínicas, Facultad de Medicina, Universidad de la República (UDELAR), Montevideo, Uruguay. Electronic address: wmanzanares@adinet.com.uy.
authors.forename: W
authors.initials: W
authors.lastname: Manzanares
mesh_terms: D018806:APACHE; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003422:Critical Care / Q000379:methods*; D016638:Critical Illness; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D015201:Meta-Analysis as Topic; D023421:Models, Animal; D009102:Multiple Organ Failure / Q000097:blood / Q000188:drug therapy; D018384:Oxidative Stress / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D020887:Selenious Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012643:Selenium / Q000097:blood; D018038:Sodium Selenite / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D005979:Glutathione Peroxidase; D020887:Selenious Acid; D012643:Selenium; D018038:Sodium Selenite
keywords: Critically ill; Estrés oxidativo; Farmaconutrición; Oxidative stress; Paciente crítico; Pharmaconutrition; Selenio; Selenium; Sepsis